genomic biomarker validation
Systematic process of demonstrating that a genomic alteration reliably predicts clinical outcomes or treatment responses in defined patient populations.
Full Definition
Genomic biomarker validation is the rigorous scientific process required to establish that a specific genomic alteration can reliably predict clinical outcomes, treatment responses, or disease progression in well-defined patient populations. This validation process typically progresses through analytical validation (demonstrating accurate and reproducible detection), clinical validation (establishing association with clinical endpoints), and clinical utility validation (proving that biomarker use improves patient outcomes). The process requires large-scale clinical studies, standardized testing methodologies, and regulatory approval pathways to ensure that genomic biomarkers provide reliable clinical value.
Usage
Usage note: Distinguish between analytical, clinical, and clinical utility validation phases.
In Context
- "Genomic biomarker validation for the novel fusion required demonstration of predictive accuracy across multiple independent clinical cohorts." — Regulatory submission
- "The genomic biomarker validation study established clear performance criteria for clinical implementation." — Clinical development report